Literature DB >> 17541020

In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired.

Ming-Dong Wang1, Vivian Franklin, Yves L Marcel.   

Abstract

BACKGROUND: ATP-binding cassette transporter A1 (ABCA1) is a key mediator of cholesterol efflux to apoA-I in cholesterol loaded macrophages, a first step of reverse cholesterol transport (RCT) in vivo. Macrophage specific abca1 inactivation or overexpression, respectively, accelerated or suppressed the development of atherosclerosis in mouse models. However, it is yet to be established that the ABCA1 effect is related to specific changes in RCT from the macrophages in vivo. METHODS AND
RESULTS: one marrow-derived macrophages from abca1-/- or abca1+/- mice were labeled with 3H-cholesterol-AcLDL or 3H-cholesterol-LDL and injected into abca1+/+ abca1+/- or abca1-/- mice. When injected into abca1+/+ mice, return of 3H-cholesterol from labeled abca1-/- macrophages to serum, liver, bile, and feces was reduced by 50% (P=0.01) compared with control. When labeled wild-type macrophages were injected into abca1-/- mice, as compared with wild-type mice, the return of 3H-cholesterol to serum, liver, bile, and feces was also reduced.
CONCLUSIONS: ABCA1 expression in macrophages contributes significantly to in vivo macrophage RCT. The important residual RCT observed from abca1-/- macrophages highlight the functionality of transporters that efflux to HDL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541020     DOI: 10.1161/ATVBAHA.107.146068

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

Review 1.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 2.  Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development.

Authors:  Geesje M Dallinga-Thie; Robin P F Dullaart; Arie van Tol
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 3.  High-density lipoprotein heterogeneity and function in reverse cholesterol transport.

Authors:  George H Rothblat; Michael C Phillips
Journal:  Curr Opin Lipidol       Date:  2010-06       Impact factor: 4.776

4.  LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo.

Authors:  Kristin L Bowden; Joshua A Dubland; Teddy Chan; You-Hai Xu; Gregory A Grabowski; Hong Du; Gordon A Francis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

5.  Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase.

Authors:  Mireille Ouimet; Vivian Franklin; Esther Mak; Xianghai Liao; Ira Tabas; Yves L Marcel
Journal:  Cell Metab       Date:  2011-06-08       Impact factor: 27.287

6.  Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1.

Authors:  Aaron M Fond; Chang Sup Lee; Ira G Schulman; Robert S Kiss; Kodi S Ravichandran
Journal:  J Clin Invest       Date:  2015-06-15       Impact factor: 14.808

7.  Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport.

Authors:  Priya Malik; Stela Z Berisha; Jennifer Santore; Colin Agatisa-Boyle; Gregory Brubaker; Jonathan D Smith
Journal:  J Lipid Res       Date:  2011-02-19       Impact factor: 5.922

Review 8.  High-density lipoprotein function, dysfunction, and reverse cholesterol transport.

Authors:  Edward A Fisher; Jonathan E Feig; Bernd Hewing; Stanley L Hazen; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12       Impact factor: 8.311

9.  Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases.

Authors:  Francois Fay; Brenda L Sanchez-Gaytan; David P Cormode; Torjus Skajaa; Edward A Fisher; Zahi A Fayad; Willem J M Mulder
Journal:  Curr Cardiovasc Imaging Rep       Date:  2013-02-01

10.  Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.

Authors:  Suguru Yamamoto; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.